

<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="https://www.w3.org/1999/xlink">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Avicenna J Med Biotech</journal-id>
      <journal-id journal-id-type="publisher-id">arij002</journal-id>
      <journal-title-group>
        <journal-title>Avicenna Journal of Medical Biotechnology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2008-2835</issn>
      <issn pub-type="epub">2008-4625</issn>
      <publisher>
        <publisher-name>Avicenna Research Institute</publisher-name>
      </publisher>
    </journal-meta>

    <article-meta>
      <article-id pub-id-type="publisher-id">ajmb60585</article-id>
      <article-id pub-id-type="doi"></article-id>
      <article-id pub-id-type="pmid"></article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
             <subject></subject> 
        </subj-group>
        <subj-group>
            <subject></subject>
        </subj-group> 
      </article-categories>
      <title-group>
        <article-title>Bactericidal Activity of Serum by Brucella Abortus RB51 Outer Membrane Protein’s  Combined by Brucella Abortus S99 Lipopolysaccharide Induction</article-title>
      </title-group>
        <contrib-group><contrib contrib-type="author"><name><surname>Hajizadeh Sisakht</surname><given-names>Behnam</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Khaledi</surname><given-names>Mansoor</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Afkhami</surname><given-names>Hamed</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Rouhi</surname><given-names>Saber</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Sepehrnia</surname><given-names>Saeed</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Fanaee</surname><given-names>Vahideh</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Karimi</surname><given-names>Hannaneh</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Malekzadegan</surname><given-names>Yalda</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Fathi</surname><given-names>Javad</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>S. Sadati </surname><given-names>Mahdi</given-names></name></contrib></contrib-group>
      <pub-date pub-type="ppub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <pub-date pub-type="epub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <volume>16</volume>
      <issue>3</issue>
      <fpage>187</fpage>
      <lpage>192</lpage>
      <history>
        <date date-type="received">
          <day>30</day>
          <month>9</month>
          <year>2023</year>
        </date>
        <date date-type="accepted">
          <day>3</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </history>
      <abstract>
      <p>
      &lt;p&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;Background: Brucellosis vaccines are designed to induce cellular immunity. An effective brucellosis vaccine could induce both cellular and humoral immunity. Serum Bactericidal Assay (SBA) is an important method for determining vaccine humoral immunity. This study is the first to observe humoral immunity in brucellosis by SBA. &lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;Methods: Extracted Brucella abortus (B. abortus) Lipopolysaccharide (LPS) and Outer Membrane Proteins (OMPs) were injected into rabbits. Group 1 was injected with 25 &amp;micro;g of LPS, Group 2 was injected with 50 &amp;micro;g of OMPs, and Group 3 was injected with 1 ml of combined vaccine, 3 times every 2 weeks. The groups were challenged with B. abortus 544 in the second injection. Sera were separated 2 weeks after the last injection. SBA was performed, and each well was streak-cultured into a plate of Brucella agar. A colony count was done for each plate. &lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;Results: Results have shown, the third injection of the combined vaccine had the highest titer of 1/64, and the efficacy of the vaccine was 87.71%. &lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;Conclusion: As a conclusion, the results of this study showed that LPS and OMP&amp;#39;s from B. abortus can provide acceptable immunity.&lt;/span&gt;&lt;/p&gt;

      </p>
      </abstract>
    </article-meta>
  </front>
    
</article>
